3 Tech Stocks that Could Soar After Earnings — Positive
AVGO MRVL NVDA 24/7 Wall Street — February 11, 2025More than a month into 2025, investors have plenty of earnings to digest.

Molson Named Official 4 Nations Face-Off™ Beer Sponsor in Canada, Hosting Watch Parties Across Montreal — Neutral
TAP TAP-A Business Wire — February 11, 2025MONTREAL--(BUSINESS WIRE)--Molson is proud to be the official beer sponsor in Canada of the 4 Nations Face-Off, an international tournament staged by the National Hockey League (NHL) and National Hockey League Players' Association (NHLPA). The tournament will feature NHL players representing Canada, Finland, Sweden and the United States, facing off in a total of seven games played from February 12th to February 20th, 2025. Four games will be played at the Bell Centre in Montreal and three games.

LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules — Neutral
LIXT GlobeNewsWire — February 11, 2025PASADENA, CALIF., Feb. 11, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 434,784 shares of its common stock at a purchase price of $2.415 per share, in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to an aggregate of 434,784 shares of common stock. The warrants will have an exercise price of …

NanoViricides announces readiness to combat bird flu with antiviral drug NV-387 — Positive
NNVC Proactive Investors — February 11, 2025NanoViricides (NYSE-A:NNVC) stated today that it is prepared to address the escalating threat of bird flu with its broad-spectrum antiviral drug, NV-387. The company asserts that NV-387 is designed to remain effective against the H5N1 virus, even as the virus undergoes rapid mutations.

The VanEck Uranium and Nuclear ETF tracks the MVIS Global Uranium & Nuclear Energy Index, focusing on uranium mining, nuclear power facilities, and related services. The ETF's assets are primarily in Utilities (49%) and Energy (36.9%), with a strong U.S. focus (48.96% of net assets). Uranium prices have fluctuated historically, with recent increases due to supply constraints and renewed interest in nuclear energy post-COVID-19 and geopolitical tensions.

Yelp Gears Up to Report Q4 Earnings: Is a Beat in the Cards? — Positive
YELP Zacks Investment Research — February 11, 2025YELP's fourth-quarter 2024 results are likely to reflect benefits from increasing advertising revenues and its AI and machine learning efforts.

Should You Buy, Hold or Sell MCK Stock Following Robust Q3 Earnings? — Positive
MCK Zacks Investment Research — February 11, 2025McKesson MCK delivered an 18% increase in revenues ($95.3 billion) and a 16% rise in adjusted operating profit during the third quarter of fiscal 2025 despite ongoing macroeconomic challenges. The company also raised its full-year guidance.

Axsome Stock Surges 20% on Auvelity Patent Settlement With Teva — Positive
AXSM Zacks Investment Research — February 11, 2025AXSM stock rises 20% as it settles Auvelity patent litigation with Teva, protecting the drug's exclusivity in the United States at least until Sept. 30, 2038.

Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial — Neutral
MBRX PRNewsWire — February 11, 2025First of many site approvals, including sites in the US, Europe and the Middle East, expected throughout Q1-Q3 2025 Company remains on track for first subject treated in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) in the first quarter of 2025 Recently amended protocol accelerates unblinding of preliminary primary efficacy data (CR) and safety/tolerability of the three arms at first 45 subjects, expected in the second half of 2025 HOUSTON , Feb. 11, 2025 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat …

Fluence Energy stock: don't hold your breath for a swift recovery — Neutral
FLNC Invezz — February 11, 2025Investors are bailing on Fluence Energy Inc (NASDAQ: FLNC) today after it reported disappointing earnings for Q1. Shares of the energy storage solutions firm are down an alarming 40% in premarket also because its management lowered guidance for both revenue and adjusted EBITDA on Tuesday.

These Analysts Slash Their Forecasts On ON Semiconductor After Downbeat Results — Negative
ON Benzinga — February 11, 2025ON Semiconductor Corp ON posted downbeat quarterly results on Monday.

These Analysts Slash Their Forecasts On ON Semiconductor After Downbeat Results — Negative
ON Benzinga — February 11, 2025ON Semiconductor Corp ON posted downbeat quarterly results on Monday.

Archer Aviation raises $300 million in BlackRock-backed funding — Positive
ACHR BLK Reuters — February 11, 2025Air-taxi maker Archer Aviation said on Tuesday it has raised $300 million in a funding round that consisted of institutional investors including accounts managed by BlackRock.

Eni Rejects Exmar's FLNG Bonus Claim in Congo LNG Dispute — Negative
E Zacks Investment Research — February 11, 2025E rejects Exmar's demand for a bonus on the FLNG Tango, a key part of the Congo LNG project, sparking a contractual dispute between the two energy firms.

PLTR, MSFT and AAPL Forecast – Major US Tech Stocks Somewhat Mixed in Premarket — Positive
AAPL MSFT PLTR FXEmpire — February 11, 2025Some of the biggest US stocks are mixed in the premarket hours of Tuesday. At this point though, the overall attitude of the US stock market remains positive.

GlobalFoundries forecasts weak Q1 amid tariff concerns and smartphone sector struggles — Negative
GFS Reuters — February 11, 2025GlobalFoundries on Tuesday forecast first-quarter revenue and profit below Wall Street estimates as the contract chipmaker braces for the potential impact of President Donald Trump's tariffs on automaker clients and a challenging smartphone market in 2025.

24/7 Market News Commentary on Direct-to-Cell Satellite Connectivity Service and Siyata Mobile — Neutral
SYTA Newsfile Corp — February 11, 2025Denver, Colorado--(Newsfile Corp. - February 11, 2025) - 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, today publishes an editorial on how direct-to-cell satellite connectivity services are an ideal opportunity for Siyata Mobile (NASDAQ: SYTA) ("Siyata") to expand its push-to-talk (PTT) device markets. To read the Direct-to-Cell Satellite Connectivity Service editorial on 247marketnews.com, please click here.

Meta Outperforms Magnificent 7 As 16-Day Streak Puts Bulls In Control — Positive
META Benzinga — February 11, 2025Meta Platforms Inc META is rewriting the record books. The stock notched its 16th straight winning session on Monday, the longest streak among the Magnificent Seven.

Jenny Horne details the latest earnings report from Shopify (SHOP). The company beat revenue expectations, and sees 1Q revenue growth in the mid-twenties percentage rate over last year's report.

Newmont Corporation (NYSE: NEM) Securities Fraud: Contact Berger Montague To Discuss Your Rights — Neutral
NEM GlobeNewsWire — February 11, 2025PHILADELPHIA, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC , with offices throughout the U.S. and in Canada, advises investors that a securities class action lawsuit has been filed against Newmont Corporation (“Newmont” or the “Company”) (NYSE: NEM) on behalf of purchasers of Newmont securities between February 22, 2024 through October 23, 2024, inclusive (the “Class Period”). Investor Deadline: Investors who purchased or acquired NEWMONT securities during the Class Period may, no later than APRIL 1, 2025 , seek to be appointed as a lead plaintiff representative of the class.
